Post-polypectomy bleeding and thromboembolism risks associated with warfarin vs direct oral anticoagulants

Table 3 Crude and adjusted odds ratios for post-polypectomy bleeding in anticoagulant users (n = 218), warfarin users (n = 145), and direct oral anticoagulants users (n = 73)

AC management during peri-endoscopic period	Crude OR (95%CI)	P value	Propensity score-adjusted OR1 (95%CI)	P value
AC users
Discontinuing AC with HPB vs continuing AC	2.0 (0.9-4.6)	0.091	2.2 (0.9-5.2)	0.069
Discontinuing AC with HPB vs discontinuing AC without HPB	7.7 (1.3-Inf)	0.023	NA	NA
Warfarin users
Discontinuing warfarin with HPB vs continuing warfarin	5.7 (1.3-25.8)	0.024	4.7 (1.0-22.1)	0.049
Discontinuing warfarin with HPB vs discontinuing warfarin without HPB	7.2 (1.1-Inf)	0.033	NA	NA
DOAC users
Discontinuing DOAC with HPB vs continuing DOAC	0.6 (0.1-3.2)	0.567	0.7 (0.1-4.5)	0.664
Discontinuing DOAC with HPB vs discontinuing DOAC without HPB	0.5 (0.4-Inf)	1.000	NA	NA

¹Propensity score estimations. Values in parentheses are percentages. Values presented with a plus/minus sign are means ± SD; bold type indicates statistical significance (P < 0.05). Continuing AC group vs standard group: Logistic regression model included 8 factors that are potentially clinically important variables; area under the ROC curve for propensity scores for the continuing AC group was 0.71 (95%CI: 0.63-0.79); standard group vs continuing warfarin group: Logistic regression model included 6 factors that are potentially clinically important variables; area under the ROC curve for propensity scores for the continuing warfarin group was 0.63 (95%CI: 0.53-0.73); standard group vs continuing DOAC group: Logistic regression model included 6 factors that are potentially clinically important variables; area under the ROC curve for propensity scores for the continuing DOAC group was 0.90 (95%CI: 0.82-0.98). NA: Not applicable; AC: Anticoagulants; CI: Confidential interval; DOAC: Direct oral anticoagulants; HPB: Heparin bridge; Inf: Infinity; OR: Odds ratio.